AKROAkero Therapeutics, Inc.

Nasdaq akerotx.com


$ 20.01 $ -0.04 (-0.2 %)    

Thursday, 02-May-2024 12:09:20 EDT
QQQ $ 423.92 $ -1.32 (-0.31 %)
DIA $ 380.74 $ -0.78 (-0.2 %)
SPY $ 501.99 $ -2.41 (-0.48 %)
TLT $ 88.63 $ 0.41 (0.46 %)
GLD $ 212.84 $ 0.38 (0.18 %)
$ 20.08
$ 20.05
$ 19.94 x 100
$ 0.00 x 0
$ 19.83 - $ 20.07
$ 11.25 - $ 58.38
1,054,519
na
1.06B
$ 0.31
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 02-29-2024 12-31-2023 10-K
2 11-13-2023 09-30-2023 10-Q
3 08-11-2023 06-30-2023 10-Q
4 05-15-2023 03-31-2023 10-Q
5 03-17-2023 12-31-2022 10-K
6 11-04-2022 09-30-2022 10-Q
7 08-04-2022 06-30-2022 10-Q
8 05-06-2022 03-31-2022 10-Q
9 02-25-2022 12-31-2021 10-K
10 11-12-2021 09-30-2021 10-Q
11 08-13-2021 06-30-2021 10-Q
12 05-13-2021 03-31-2021 10-Q
13 03-16-2021 12-31-2020 10-K
14 11-12-2020 09-30-2020 10-Q
15 08-12-2020 06-30-2020 10-Q
16 05-13-2020 03-31-2020 10-Q
17 03-16-2020 12-31-2019 10-K
18 11-12-2019 09-30-2019 10-Q
19 08-12-2019 06-30-2019 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 b-of-a-securities-reinstates-neutral-on-akero-therapeutics-announces-30-price-target

B of A Securities analyst Alexandria Hammond reinstates Akero Therapeutics (NASDAQ:AKRO) with a Neutral and announces $30 pr...

 akero-therapeutics-publishes-phase-2b-symmetry-cohort-d-study-in-clinical-gastroenterology-and-hepatology

As reported previously, the addition of EFX to GLP-1 receptor agonist therapy had a safety and tolerability profile comparable ...

 akero-therapeutics-prices-public-offering-of-11m-common-stock-at-29share

The comnay announced the pricing of an underwritten public offering of 11,000,000 shares of its common stock at a public offeri...

 ubs-maintains-buy-on-akero-therapeutics-raises-price-target-to-42

UBS analyst Eliana Merle maintains Akero Therapeutics (NASDAQ:AKRO) with a Buy and raises the price target from $39 to $42.

 hc-wainwright--co-maintains-buy-on-akero-therapeutics-raises-price-target-to-50

HC Wainwright & Co. analyst Ed Arce maintains Akero Therapeutics (NASDAQ:AKRO) with a Buy and raises the price target fr...

 akero-therapeutics-begins-public-offering-of-300m-of-shares-of-its-common-stock

All of the shares in the proposed offering are being offered by Akero Therapeutics. In addition, Akero Therapeutics intends to ...

 why-bitdeer-technologies-shares-are-trading-higher-by-10-here-are-other-stocks-moving-in-mondays-mid-day-session

Shares of Bitdeer Technologies Group (NASDAQ: BTDR) rose sharply during Monday’s session after the company reported prelimina...

 akero-therapeutics-stock-is-soaring-monday---heres-why

Akero Therapeutics success in HARMONY Phase 2b study for efruxifermin. EFX demonstrated sustained efficacy and well-tolerance, ...

Core News & Articles
Market-Moving News for March 4th
03/04/2024 13:47:02

AKRO: 99% | Akero Therapeutics Released Preliminary Topline Week 96 Results From HARMONY Phase 2B Study Of Efruxifermin For Pre...

 akero-therapeutics-released-preliminary-topline-week-96-results-from-harmony-phase-2b-study-of-efruxifermin-for-pre-cirrhotic-metabolic-dysfunction-associated-steatohepatitis-fibrosis-stage-2-or-3

50mg (75%, p<0.001) and 28mg (46%, p=0.07) EFX groups demonstrated ≥1 stage improvement in fibrosis without worsening of M...

 super-micro-computer-deckers-outdoor-and-other-big-stocks-moving-higher-in-mondays-pre-market-session

U.S. stock futures were mixed this morning, with the Dow futures trading lower by around 50 points on Monday. Shares of Super ...

 hc-wainwright--co-maintains-buy-on-akero-therapeutics-raises-price-target-to-43

HC Wainwright & Co. analyst Ed Arce maintains Akero Therapeutics (NASDAQ:AKRO) with a Buy and raises the price target fr...

 akero-therapeutics-q4-eps-099-down-from-049-yoy-cash-cash-equivalents-short-term-and-long-term-marketable-securities-of-5693m-is-will-be-sufficient-to-fund-the-companys-current-operating-plan-into-2026

Akero Therapeutics (NASDAQ:AKRO) reported quarterly losses of $(0.99) per share. This is a 102.04 percent decrease over losses ...

 why-mercadolibre-shares-are-trading-lower-by-around-10-here-are-other-stocks-moving-in-fridays-mid-day-session

Shares of MercadoLibre, Inc. (NASDAQ: MELI) fell sharply during Friday’s session after the company reported fourth-quarter fin...

 carvana-posts-q4-results-joins-legalzoomcom-comfort-systems-and-other-big-stocks-moving-higher-on-friday

U.S. stocks were mostly higher, with the Dow Jones index gaining more than 100 points on Friday.

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION